Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials

BACKGROUND: Many retrospective studies suggest that risk improvement may be a suitable efficacy surrogate endpoint for pulmonary arterial hypertension (PAH) medication trials. This prospective multicenter study assessed the efficacy of domestic ambrisentan in Chinese PAH patients and observed risk i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, An, Chen, Mengqi, Zhuang, Qi, Guan, Lihua, Xie, Weiping, Wang, Lan, Huang, Wei, Cheng, Zhaozhong, Yu, Shiyong, Zhou, Hongmei, Shen, Jieyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291317/
https://www.ncbi.nlm.nih.gov/pubmed/37378404
http://dx.doi.org/10.3389/fcvm.2023.1142721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291317/
https://www.ncbi.nlm.nih.gov/pubmed/37378404
http://dx.doi.org/10.3389/fcvm.2023.1142721

Ejemplares similares